Skip to main content
Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.670
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
2.650
-0.020 (-0.75%)
After-hours: Apr 28, 2026, 7:30 PM EDT

Spero Therapeutics Revenue

In the year 2025, Spero Therapeutics had annual revenue of $66.80M with 39.24% growth. Spero Therapeutics had revenue of $41.30M in the quarter ending December 31, 2025, with 174.51% growth.

Revenue (ttm)
$66.80M
Revenue Growth
+39.24%
P/S Ratio
2.31
Revenue / Employee
$2,672,080
Employees
25
Market Cap
154.57M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202566.80M18.83M39.24%
Dec 31, 202447.98M-55.80M-53.77%
Dec 31, 2023103.78M50.27M93.95%
Dec 31, 202253.51M35.25M193.10%
Dec 31, 202118.26M8.93M95.67%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Agenus 114.20M
ProQR Therapeutics 19.19M
Fate Therapeutics 6.65M
Alps Group 3.74M
Humacyte 2.04M
Oramed Pharmaceuticals 2.00M
Molecular Partners AG 856.30K
Revenue Rankings

SPRO News

More News